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health outcome estimates, findings have important implications for health care 
resource spending and to assess the cost-effectiveness of deviated first line treat-
ment practices that have emerged in the treatment of advanced ovarian cancer 
patients.
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DireCt MeDiCal Costs (DMC) of treatiNg Prostate CaNCer iN a MeDiCal 
CooPerative HMo iN Brazil: results froM a loNgituDiNal aNalysis of 
aN aDMiNistrative DataBase
Santos M.C.L., Luiz C.B., Maturana M.S.
Unimed São José do Rio Preto, São José do Rio Preto, Brazil
Objectives: The aim of this study is to determine direct medical costs of treating 
patients with prostate cancer from the perspective of a Brazilian HMO. MethOds: 
An administrative database containing inpatient and outpatient claims of Unimed 
São Jose do Rio Preto, a HMO in São Paulo state with 131,064 beneficiaries, was 
reviewed from Jan/2004 to Dec/2013. Eligibility criteria were patients with a medical 
claim associated with prostate cancer (ICD-10 code C61) from Jun/2012 to Dec/2012, 
with more than 30-days of follow-up data. Diagnosis date for these patients were 
ascertained and they were followed until death or loss of follow-up, whichever 
comes first. Outcome was direct medical costs (DMC), calculated as the sum of the 
medical claims for each patient included in the analysis. DMC-per-year associated 
with prostate cancer was calculated and stratified by treatment choice (wait-and-
see, local therapy, androgen deprivation, chemotherapy). Results: 312 patients 
met eligibility criteria, with a median follow-up of 2.94 years. Total DMC in this 
population was R$ 4,247,664.42, from which R$ 1,675,255.31 (39.4%) are related to 
diagnostic exams, R$ 792,795.52 (18.7%) to hospitalizations, R$ 615,164.85 (14.5%) 
to radiotherapy, R$ 333,388.04 (7.8%) to chemotherapy and R$ 831,060.70 (19.6%) to 
other outpatient costs. A total of 143 patients started treatment as “wait-and-see” 
with average DMC-per-year related to prostate cancer of R$ 432.44/year; for patients 
starting local therapy, there were 162 patients with average DMC-per-year of R$ 
4,640.95/year; the androgen deprivation group had 19 patients with average DMC-
per-year of R$ 5.850,15/year and 4 patients started chemotherapy with an average 
DMC-per-year of R$ 33.773,22/year. cOnclusiOns: Patients with prostate cancer 
represent a significant economic burden to private payers, escalating as disease 
progresses. Patients starting chemotherapy may cost per year approximately 6 times 
the cost of patients in early stages of the disease.
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assessiNg tHe eCoNoMiC BurDeN of aDverse effeCts (aes) assoCiateD 
witH MetastatiC MelaNoMa (MM) treatMeNts iN gerMaNy
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Objectives: This study estimated the per-event cost and economic burden 
associated with managing the most common and/or severe AEs associated with 
3 common treatment categories (chemotherapy [CT], targeted therapy [TT], and 
immunotherapy [IT]) for MM in Germany from the statutory health insurance (SHI) 
system perspective. MethOds: A literature review was conducted to evaluate the 
incidence and types of AEs associated with the 3 treatment categories. A total of 
29 AEs (CT:11; TT:11; and IT:7), all-severity grades (Gr) occurring in > 20% or Gr 3/4 
occurring in > 5%, were selected. Medical resource use related to the management 
of AEs was assessed by conducting 2 blinded Delphi panel cycles with 9 clinicians. 
Published unit costs were used to estimate the costs per AE and then combined with 
AE incidence (assuming 1 occurrence/patient/cycle), treatment usage, and 1-year 
prevalence of MM (1165 cases) to estimate the treatment burden in Germany for a 
single AE occurrence. Results: The most cost-intensive AEs were all Gr 3/4. For CT, 
the most cost-intensive AEs were neutropenia/leukopenia and thrombocytopenia, 
representing a mean cost per patient of € 1744 and € 1095, respectively. For TT, AEs 
were rash and squamous cell carcinoma (SCC), with a mean cost of € 392 and € 323, 
respectively. For IT, AEs were colitis and diarrhea, with a mean cost of € 1444 and 
€ 1274, respectively. The top 5 AEs across all 3 treatment categories contributing most 
to the burden were all Gr 3/4 and included neutropenia/leukopenia (mean total cost 
of € 110,627), colitis (€ 40,534), diarrhea (€ 37,874), SCC (€ 26,237), and immune-related 
hypophysitis (€ 23,375). cOnclusiOns: Substantial costs in the management of 
AEs are associated with MM therapies in Germany. The overall burden is likely to 
be underestimated since it does not account for AE recurrence.
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Objectives: To examine AE rates and associated costs among mCRC patients 
treated with bevacizumab (BV) or cetuximab (CET). MethOds: Using a large 
national US claims database from 1/2008-3/2012, patients with mCRC were identi-
fied (≥ 2 claims for colon or rectal cancer and metastatic disease), with enrollment 
in the health plan for ≥ 6m before and after the 1st metastatic claim date. Patients 
received BV or CET during 1st line (LOT1) and/or 2ndline (LOT2) therapy. LOT2 was 
defined as addition of any new agent ≥ 28d after start of LOT1. AEs, identified with 
ICD-9 codes on health care claims, were assessed from start of 1st targeted therapy 
in LOT1 or LOT2 to the last targeted therapy date+28d or a new LOT. Incident Rate 
Ratios (IRR) were calculated for each AE (incidence rate for CET/incidence rate for 
BV). Multivariate regression analyses assessed medical costs. Results: In LOT1, 
there were 1,255 BV and 119 CET patients; in LOT2, 671 BV and 157 CET patients. The 
CET cohort had higher incidence rates (IRR> 1; p< 0.05) in LOT1 for: dermatologic 
events (IRR= 8.67), GI (IRR= 1.38), DVT (IRR= 2.58), metabolism (IRR= 2.11), hemorrhage 
(IRR= 2.32) and infusion reactions (IRR= 1.81). In LOT2, the CET cohort had higher 
rates (p< 0.05) for: dermatologic (IRR= 9.28), GI (IRR= 1.36), DVT (IRR= 1.75), metabo-
lism (IRR= 1.75), infusion reactions (IRR= 1.54), hemorrhage (IRR= 2.32); and Sepsis 
Objectives: To assess health care resource utilization and cost of cervical can-
cer from the perspective of British Columbia’s health care system. MethOds: 
Retrospective observational data on women diagnosed with cervical cancer between 
2004 and 2009 was utilized to calculate patient-level resource utilization from diag-
nosis to death or 5-year discharge. Domains of resource use included hospitaliza-
tion, chemotherapy, radiotherapy, brachytherapy, medically necessary services such 
as laboratory, physician and diagnostics billed under B.C.’s Medical Services Plan and 
medication dispensed under B.C.’s Pharmacare program. Unit costs were applied to 
health care resources, producing per-patient costs. Relevant costs, presented in 2012 
CDN dollars, were further separated by chemotherapy protocol, stage at diagnosis, 
screening history, progression date and age. Results: The average cost of treating 
cervical cancer in B.C. was $32 023, (95% CI: $29 785 - $34 260). Hospital costs were 
the largest proportion of cost at a mean proportion of 37.8% (95% CI: 35.8, 39.8) of 
total cost. Mean length of inpatient hospital visits was 11.2 days, with 2 outpatient 
hospital visits per patient. Costs were also calculated by relevant clinical subgroups, 
including progression, age, stage, screening history and treatment protocol on cost 
and resource utilization. cOnclusiOns: Cervical cancer resource utilization and 
costs are substantial in B.C.’s health care system. Such data is necessary for decision 
makers in designing and implementing screening and disease management policy. 
Results will provide inputs for the HPV FOCAL Study, a prospective investigation 
into the cost-effectiveness of utilizing the detection of HPV infection as a primary 
screening tool in B.C.
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Objectives: Prolonged air leak (PAL) following lung resection results in increased 
length of stay (LOS), morbidity and costs. Pulmonary resection can be performed 
open or by video-assisted thoracic surgery (VATS). This study quantifies the total 
health care utilization and expenditures in patients who experienced a PAL after 
undergoing lung resection. MethOds: This study utilized administrative health 
claims data from MarketScan® commercial and Medicare databases from 2009-
2011. Patients were included if they underwent a lobectomy, segmentectomy or 
wedge resection. Patients were classified as having a PAL if LOS was greater than 
5 days with a simultaneous ICD-9 code of 512.1 or 512.2 for pneumothorax. Data 
were analyzed on complications, LOS, readmission, and expenditures. Multivariable 
logistic regression analysis modeled for the binary outcome of PAL (yes or no). 
Expenditures and LOS were modeled using generalized linear models with a gamma 
distribution and log-link. Results: 27,366 records were analyzed, including 10,585 
lobectomies (39%), 2,100 segmentectomies (8%) and 14,681 wedge resections (53%). 
Multivariable logistic regression showed that open procedures are 40% (95% CI: 26% 
to 55%; p< 0.0001) more likely to suffer PALs than VATS. When PALs occur, open pro-
cedures are associated with longer LOS than VATS (12.2 versus 11.4 days; p= 0.0067) 
and are 75% (95% CI, 19% to 155%; p= 0.0040) more likely to get readmitted within 
30 days. Health care expenditures for patients with PALs are higher than for those 
without ($59,713 versus $44,077; p< 0.0001). cOnclusiOns: PALs cause an eco-
nomic burden of ~$15,000 per patient in our health care system. VATS approach is 
associated with a significant reduction in PALs and total inpatient expenditures. 
In addition, when PALs occurred, VATS procedures were associated with a shorter 
LOS and reduced likelihood of readmission - thus reducing overall expenditure.
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CoHort of elDerly PatieNts
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Objectives: Use of primary chemotherapy in the treatment of advanced ovarian 
cancer has increased in recent years. While, an on-going deliberation on the useful-
ness of this practice compared to primary debulking surgery (PDS) continues till 
date, none has studied monetary implications of the varying treatment practices. 
In this study, we estimate the lifetime costs of ovarian cancer by primary treat-
ment. MethOds: A cohort of elderly women (≥ 65 years) with stage III and IV 
ovarian cancer was identified from the Surveillance, Epidemiology and End Results-
Medicare linked database from January 1, 2006- December 31, 2009. Cost analysis 
was conducted from a payer (i.e., Medicare) perspective, and direct medical costs 
incurred by Medicare were integrated for each patient. Cumulative treatment costs 
were estimated using phase of care approach (wherein the mean phase specific 
costs were weighted with the survival function), starting from date of diagnosis 
until death or last follow-up (December 2010). All costs were adjusted for geographic 
variation and inflation over time and discounted at a rate of 3%. Results: Among 
3408 patients, 17.3% (n= 591) received PDS, 57.2% (n= 1951) received primary chemo-
therapy (only 5.6% (n= 192) received subsequent surgery) and 25.4% (n= 866) did not 
receive either surgery or chemotherapy within 12 months of diagnosis. The mean 
lifetime costs in patients receiving no cancer directed treatment was $24,467; with 
the resultant incremental mean lifetime costs estimated as $37,434, $79,089 and 
$45,301 for patients receiving PDS, primary chemotherapy with subsequent surgery, 
and primary chemotherapy without surgery, respectively. cOnclusiOns: The mean 
lifetime cost in patients receiving neoadjuvant chemotherapy followed by delayed 
debulking surgery is double the cost in those receiving PDS. In conjunction with 
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incidence (assuming 1 occurrence/patient/cycle), treatment usage, and 1-year 
prevalence of MM (2124 cases) to estimate the treatment burden in Australia for a 
single AE occurrence. Results: The most cost-intensive AEs were all Gr 3/4. For TT, 
the most cost-intensive AEs were squamous cell carcinoma (SCC) and rash, with 
a mean cost per event per patient of A$228 and A$223, respectively. For IT, they 
were colitis and diarrhea, with a mean cost of A$1471 and A$1333, respectively. 
For CT, they were neutropenia/leukopenia and anaphylaxis, representing a mean 
cost of A$1005 and A$381, respectively. Across all 3 treatment categories, the top 
4 AEs with the highest burden were all Gr 3/4 and included neutropenia/leukope-
nia (mean total cost of A$92,453), colitis (A$72,346), diarrhea (A$69,399), and SCC 
(A$30,636). cOnclusiOns: In Australia, costs for management of AEs associated 
with MM therapies can be substantial. Since we did not account for multiple AE 
occurrences, the total burden is likely to be an underestimate.
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oNCology Care iN tHe uNiteD states
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Objectives: To understand the proportion of total medical costs attributed to can-
cer drug treatment in oncology patients, with a focus on breast and prostate can-
cer. MethOds: Literature review conducted using PubMed, Medscape and Google 
to identify and retrieve studies in cancer patients reporting total medical costs and 
cost components, particularly cancer drug treatment costs. All studies reporting 
data on US American patients published in English language between 2009 and 2013 
were included. Results: A total of 5565 studies were reviewed, 14 of which were 
relevant and included. Total medical costs and cost components varied substantially 
by tumor type and location, cancer stage, phase of care, study design, payers and 
the way drug and treatment costs were defined and reported. In 2011, oncology 
care costs accounted for $125 billion. Prescription drug costs were 1.8–13.9% of total 
cancer care costs, with 13.9% representing the proportion of costs during the last six 
months of life. Studies of breast cancer patients reported that drugs accounted for 
2.4–37.0% of total costs, with the lowest proportion occurring in newly diagnosed 
and the highest in metastatic patients, respectively. Outpatient visits were the pri-
mary cost driver, accounting for 64.0-82.0% of total costs. Among patients receiving 
chemotherapy as their primary treatment, chemotherapy costs accounted for 25.0% 
and other medications (e.g., analgesics, sedatives, anti-emetics, antidepressants) 
accounted for 26.0% of total costs. None of the prostate cancer studies identified met 
the research inclusion criteria. cOnclusiOns: Studies on drug treatment costs are 
limited and results vary substantially depending on patient clinical characteristics, 
cancer stage, and disease progression. Existing studies suggest that although medi-
cal costs are high overall, cancer drug treatment costs only contribute 1.8–13.9% of 
total cancer costs, and 2.4–37.0% in breast cancer.
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Objectives: Manufacturer listed prices do not represent real transactions prices 
but are often used to set up reimbursement rates for third-party payers. This study 
evaluates approvals, discontinuations, and price trends of oncology drugs approved 
by the US Food and Drug Administration (FDA) in the period 1990-2013. MethOds: 
Drug regulatory information derived from the FDA. Average wholesaler prices (AWP) 
per unit were collected from the RedBook. Annual average price changes were cal-
culated for each drug as the increase in prices from market entry to Dec-31-2013 
divided by the number of years between the effective dates of those prices. Prices 
were converted to 2013 year dollars using the consumer price index (CPI). Descriptive 
statistics and 95% confidence intervals and t-tests were performed in the analy-
sis. Results: The FDA listed 165 approved oncology therapeutic drugs (44 biologics 
and 121 chemical entities) in the period of analysis. The FDA approved 31 products 
(18% of total) before the 1980s, 11 (6.7%) in the 1980s, 50 (30.3%) in the 1990s, 48 
(29.1%) in the 2000s, and 25 (15.2%) in 2010-2103. There were 45 (27.3%) products 
with at least one FDA approved orphan indication. There were 10 products (6.1% 
of approvals) discontinued. There were 45 products with complete price history 
from approval to January 1,2014, and 2 had generic competition. The CPI adjusted 
average annual AWP price increase was 10.2%±21.0% (95%CI:8.2%-12.1%); with an 
average 9.18±6.59 years in the market. The average annual AWP increase was higher 
for products approved in the 1990s (20.9%±34.8%) than for those approved in the 
2000’s (5.0%±5.2%) and 2000-2013 (6.3%±9.8%). Chemical entities and drugs with 
orphan indications had higher AWP price increases than biologics and non-orphan 
drugs, respectively. cOnclusiOns: Manufacturer listed prices of oncology products 
approved in the period 1990-2013 grew faster than the inflation. Price increases were 
higher for orphan drugs and chemical entities.
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gastroiNtestiNal stroMal tuMor (gist) treateD witH iMatiNiB
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Objectives: Since approval of imatinib, systemic therapy (ST) for gastrointestinal 
stromal tumors (GIST) has changed considerably. This study evaluated treatment pat-
terns and costs across 3 large retrospective databases among GIST patients receiv-
(IRR= 2.68); BV had higher proteinuria (IRR= 0.64; p< 0.01). GI perforation incidence 
rates trended higher (p> 0.05) with BV (LOT1:0.02 vs. 0; LOT2:0.001 vs. 0). BV patients 
had lower per-patient per-month (PPPM) total costs (LOT1 adj. difference: –$4,202, 
p< 0.01; LOT2: -$3,776, p= 0.01), and PPPM AE medical costs (LOT1:-$5,851, p< 0.01; 
LOT2: –$4,293, p= 0.02). cOnclusiOns: BV during first or second line mCRC treat-
ment was associated with lower AE rates and lower PPPM costs compared to CET. 
Limitations include the inability to distinguish events related to targeted vs. chemo 
agents and high baseline rates of certain events (e.g., hypertension).
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exPeNses aMoNg 10 MillioN CoMMerCially iNsureD MeMBers
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Objectives: Early stage breast cancer is treated with surgery plus adjuvant ther-
apy which may include radiation, cytotoxic chemotherapy, and hormonal therapy 
resulting in substantial cost variation. Understanding costs is essential to estab-
lishing aberrant billing and clinical practice variation. MethOds: This naturalistic 
study assessed 10 million commercial members younger than 65. Claims data from 
January 2009 through December 2012 was assessed. During 2010-2011, members 
with primary breast cancer surgery, defined as the first diagnosis coded breast can-
cer claim lumpectomy or mastectomy claim and continuous enrollment > = 365 days 
before and after surgery were identified and categorized into three groups: receiving 
no chemotherapy, cytotoxic chemotherapy without trastuzumab, or chemotherapy 
including trastuzumab. Members were excluded if there was claims evidence for 
metastatic breast cancer or any radiation therapy before surgery. The start date was 
the first cytotoxic chemotherapy claim, if it occurred prior to surgery, otherwise it 
was the surgery date. Medical and pharmacy claims expenses were summed for 
the post 365-day interval beginning at the earlier of the surgery date or start of 
neoadjuvant chemotherapy. Results: 5,050 members met analysis criteria; 2,437 
(48.3%) no chemotherapy, 1,965 (38.9%) chemotherapy without trastuzumab, and 648 
(12.8%) chemotherapy plus trastuzumab, and average medical plus pharmacy claims 
expense for members in these categories for the 365-day interval was $49,392, 
$99,646, and $169,083, respectively. Average chemotherapy costs for members receiv-
ing chemotherapy without trastuzumab (n= 1,965) was $11,695 and for members 
with trastuzumab (n= 648) $74,048. cOnclusiOns: The cost of early stage breast 
cancer therapy varies by the three described treatment categories. Compared with 
the no chemotherapy group, average expenses for all medical and pharmacy claims 
in a 365-day interval was $50,254 higher for members who received chemotherapy 
without trastuzumab, and $119,691 higher for the group with chemotherapy includ-
ing trastuzumab. Member cost distributions between and within these categories 
will be helpful in developing managed care strategies.
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Objectives: Chemotherapy (CT), targeted therapy (TT), and immunotherapy (IT), 
which are commonly used to treat MM, are often associated with adverse effects 
(AEs). This study estimated the per-event cost and economic burden associated 
with managing the most common and/or severe AEs for these 3 treatment cat-
egories from the UK National Health Service perspective. MethOds: A literature 
review evaluated the incidence and types of AEs associated with the 3 treatment 
categories. A total of 29 AEs (CT:11; TT:11; and IT:7), all-severity grades (Gr) occurring 
in > 20% or Gr 3/4 occurring in > 5%, were selected. Medical resource use related to 
the management of AEs was assessed by conducting 2 blinded Delphi panel cycles 
with 4 clinicians. Published unit costs were used to estimate the costs per AE and 
then combined with AE incidence (assuming 1 occurrence/patient/cycle), treatment 
usage, and 1-year prevalence of MM (2027 cases) to estimate treatment burden in the 
UK for a single AE occurrence. Results: For CT, the most cost-intensive AEs were 
Gr 3/4 peripheral neuropathy and thrombocytopenia, representing a mean cost per 
event per patient of £432 and £277, respectively. For TT, they were Gr 3/4 squamous 
cell carcinoma (SCC) and Gr 1/2 skin papilloma, with a mean cost of £1281 and £845, 
respectively. For IT, they were Gr 3/4 diarrhea and colitis, both with a mean cost 
of £2836. The top 5 AEs with the highest treatment burden across all 3 categories 
included Gr 3/4 SCC (mean total cost of £202,493), Gr 3/4 diarrhea (£132,032), Gr 
1/2 skin papilloma (£125,995), Gr 3/4 colitis (£124,695) and Gr 3/4 immune-related 
hypophysitis (£98,393), and Gr 1/2 hyperkeratosis (£70,292). cOnclusiOns: In the 
UK, costs for management of AEs associated with MM therapies can be substantial. 
The total burden may be underestimated since it does not account for AE recurrence.
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Objectives: Targeted therapy (TT), immunotherapy (IT), and chemotherapy (CT), 
which are commonly used in the treatment of MM, are frequently associated with 
adverse effects (AEs). This study estimated the per-event cost and economic burden 
associated with managing the most common and/or severe AEs for these 3 treat-
ment categories from the Australian statutory health insurance system perspec-
tive. MethOds: The study involved a literature review to evaluate the incidence 
and types of AEs associated with the 3 treatment categories. A total of 29 AEs (CT:11; 
TT:11; and IT:7), all-severity grades (Gr) occurring in > 20% or Gr 3/4 occurring in 
> 5%, were selected. Medical resource use related to the management of AEs was 
assessed by conducting 2 blinded Delphi panel cycles with 5 clinicians. Published 
unit costs were used to estimate the costs per AE and then combined with AE 
